BE Biosol, Gates Foundation ink pact for anaemia injection FCM

Direct Source Verification: This story is aggregated from The Hindu (thehindu.com). Full reporting rights and copyright belong to the primary publisher.
You don’t have any Active Subscription.

You don’t have any Active Subscription.

Account subscription benefits alongside Premium Stories, Editorials, Opinions and more. Unlock these with Subscription

The agreement is for development of Ferric Carboxymaltose (FCM) injection and to improve accessibility of the drug in multiple countries. | Photo Credit: Arrangement

BE Biosol, the CDMO arm of vaccine maker Biological E., has entered into an agreement with the Gates Foundation for development of Ferric Carboxymaltose (FCM) injection and to improve accessibility of the drug to treat iron deficiency anaemia in multiple countries.

The Gates Foundation will support BE Biosol for scale-up and clinical development of the product for the target markets. BE Biosol will leverage its research and development capabilities and manufacturing infrastructure to support the programme, the company said in a release on the agreement to expand access to FCM injection in Africa.

BE Biosol aims to establish a differentiated, cost-competitive offering and build a meaningful presence in the markets by leveraging its manufacturing scale and proprietary API technology. The collaboration with the Gates Foundation reflects confidence in BE Biosol’s capabilities to develop and manufacture technologically demanding sterile formulations at competitive costs and scale. More broadly, it reinforces the company’s strategy to establish itself as a globally competitive CDMO platform across complex biologics and pharmaceutical modalities, said Narender Mantena, Managing Director.

BE Biosol’s manufacturing facility is in Shamirpet, Telangana. Since its commissioning in 2018 it has undergone multiple inspections and received approvals multiple times from leading regulatory agencies, including the U.S. FDA, Infarmed (Portugal), the UK MHRA and Brazil’s ANVISA, the company said in a release.

Comments have to be in English, and in full sentences. They cannot be abusive or personal. Please abide by our community guidelines for posting your comments.

We have migrated to a new commenting platform. If you are already a registered user of The Hindu and logged in, you may continue to engage with our articles. If you do not have an account please register and login to post comments. Users can access their older comments by logging into their accounts on Vuukle.

Original Source
https://www.thehindu.com/news/cities/Hyderabad/be-biosol-gates-foundation-ink-pact-for-anaemia-injection-fcm/article71720996.ece
Visit The Hindu ↗
SHARE STORY:
𝕏 f in

Related Coverage in Markets